Journals / Türk Hematoloji Onkoloji Dergisi / 2004 / Cilt: 14 - Sayı: 2

Chemoradiotherapy results of eusophageal cancer

Özefagus kanserlerinde kemoradyoterapi sonuçları

Pages
68–73
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The overall median survival was 8 months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this prospective clinical trial we evaluated the efficacy and toxicity of chemoradiotherapy 25 medically inoperabl (or refusing surgery) patients with locally advanced eusophageal cancer.
📊
Key Findings & Data:They were given 50 Gy external radiotherapy in 25 fractions over 5 weeks, plus concomittant cisplatin intravenously on the first day of weeks 1, 5, 8, 11, and 5-fluorouracil, 1 g/m2 per day by continuous infusion on the first 4 days of weeks 1, 5, 8, and 11.
💡
Conclusion & Impact:The overall median survival was 8 months.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:İleriye dönük çalışma · İlaç tedavisi · Özofagus neoplazmları

Abstract

In this prospective clinical trial we evaluated the efficacy and toxicity of chemoradiotherapy 25 medically inoperabl (or refusing surgery) patients with locally advanced eusophageal cancer. They were given 50 Gy external radiotherapy in 25 fractions over 5 weeks, plus concomittant cisplatin intravenously on the first day of weeks 1, 5, 8, 11, and 5-fluorouracil, 1 g/m2 per day by continuous infusion on the first 4 days of weeks 1, 5, 8, and 11. The overall median survival was 8 months. One year and 2-year overall survival rates were 48% and 31%, respectively. The treatment was moderately tolerated, and treatment-related death was not observed.

Özet

Bu prospektif çalışma lokal ileri evre, medikal inoperabl veya operasyonu kabul etmeyen özofagus kanserli olgularda eş zamanlı olarak uygulanan kemoradyoterapinin palyasyon, sağkalım avantajı ve tedavi toksisitesini değerlendirmek amacıyla yapılmıştır. KPS ≥70 olan 25 (kadın: 13, erkek: 12) hastaya radyoterapi ile eş zamanlı kemoterapi verildi. Hastalara 2 Gy'lik fraksiyonlarla toplam 50 Gy eksternal radyoterapi uygulandı. Radyoterapinin 1. ve 5. haftasında Sisplatin + 5 Fluorourasil (FU) (sisplatin 1. gün 75 mg/m2, 5 FU 1-4. günler 1000 mg/m2 sürekli infüzyon) ve radyoterapi sonrası 21 günde bir olmak üzere aynı protokolle 2 kür daha kemoterapi uygulandı. Medyan sağkalım 8 aydır (2-41 ay). Bir yıllık genel sağkalım %48, 2 yıllık sağkalım %31 bulunmuştur. Kemoradyoterapi orta derecede tolere edilmiştir ve tedaviye bağlı ölüm görülmemiştir.

🔖

Cite This Article

KOÇ, M., KARSLIOĞLU, İ., SEZEN, O., ERTEKİN, M. V., TEKİN, S. B. (2004). Chemoradiotherapy results of eusophageal cancer. Türk Hematoloji Onkoloji Dergisi, Cilt: 14 - Sayı: 2, 68–73. https://ajindex.com/articles/402088

References (3)

  1. Day NE, Varghese C. Oesophageal cancer. Cancer S urv 19/20:43-54, 1994 2. Heath HI, Heitmiller RF, Forastiere AA. Esophageal Cancer. In:Clinical Oncology (eds: Lenhard LE, Osteen RT, Gansler T). The American Cancer Society, Inc., Atlanta, Goergia, 331-343,2001. 3. Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma: I. A critical review of radiotherapy. Br J Surg 67:457-61, 1980 4. Gen JI. The use of chemoradiotherapy in esophageal cancer. Eur J Cancer 38:300-313, 2002 5. Keane TJ, Harwood AE, Elhakim T, et al. Radical radiation therapy with 5-fluourouracil infusion and mitomycin C for oesophageal squamous carcinoma. Radiother Oncol 4:205-210,1985. 6. John MJ, Flam MS, Mowry PA, et al. Radiotherapy alone and chemoradiation for non-metastatic esophageal carcinoma. Cancer 63: 2397-2403, 1989. 7. Chan A, Wong A, Arthur K. Concomittant 5- fluorouracil infusion, mitomycin C and radical radiation therapy in esophageal squamous cell carcinoma. Int J Radiat Biol Phys 1989
  2. 65,1989. 8. Lokich J, Shea M, Chaffey J. Sequential infusional 5-fluorouracil followed by concomittant radiation for tumors of the esophagus and gastroesophageal junction. Cancer 60:275-279, 1987. 9. Muller JM, Erasmi H, Stelzner M, Zieran U, Pichlmaier H. Surgical therapy for oesophageal carcinoma. Br J Surg 77:845-857, 1990. 10. Chan A, Wong A. Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma. Int J Radiat Biol Phys 45:265-270, 1999. 11. Sagar PM, Gauperaa T, Sue-Ling H, Mcmahon MJ, Johnston D. An audit of the treatment of cancer of the oesophagus. Gut 35:941-945, 1994 12. Richmond J, Seydel HG, Bae Y, Lewis J, Burdakin J, jacopsen G. Comparison of three treatment strategies for esophageal cancer within a single institute. Int J Radiat Biol Phys 3:1617-1620,1987. 13. Leichman L, Herskovic A, Leichman CG, et al. Nonoperative therapy for squamous-cell cancer of the esophagus. J Clin Oncol 5:365-370,1987. 14. Burmeister BH, Denham JW, O'Brien M, et al. Combined modality therapy for esophageal carcinoma: preliminary results from a large Australion multicentre study. Int J Radiat Biol Phys 32:997-1006, 1995. 15. Murakami M, Kuroda Y, Okamoto Y et al.Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma. Int J Radiat Biol Phys 40
  3. 1059, 1998. 16. Araujo CM, Souhami L, Gil RA, et al. A randomized trial comparing radiatio